Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Overview of efficacy, side effects, and key challenges GLP-1 receptor agonists such as semaglutide and liraglutide, as well as combination agents like tirzepatide (which adds glucose-dependent insulinotropic polypeptide receptor agonism)all hereafter referred to as GLP-1s for brevityare effective new agents for obesity treatment which demonstrate weight reduction, weight maintenance, and reduced morbidity and mortality
10.1016/j.cell.2017.10.035 55 SmithC
Losing and maintaining weight loss of more than 10% is associated with significantly reducing complications associated with obesity, including hypertension, type 2 diabetes, and heart disease
Endocrinology (2015) 156(10):355969
What This Transition Could Mean For Cost And Access Shifting from injectable to oral GLP-1s may improve access and adherence by simplifying storage and administration
